| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.063 | 0.03 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.03 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.03 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.03 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.078 | 0.03 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.069 | 0.03 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.075 | 0.03 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.077 | 0.04 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.04 |